KINASE INHIBITORS
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase II PACE Trial (NCT01207440) in Patients (pts) With Ph+ Leukemia
In a retrospective analysis of data from the phase 2 PACE trial of patients with refractory chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia receiving ponatinib, an independent Endpoint Adjudication Committee found lower rates of arterial occlusive events (AOEs) and serious AOEs than were reported by the PACE trial investigators, suggesting an overestimation.
2020 ASCO Annual Meeting (Abstract/Poster)
